Understanding pancreatic fat and cyst features in patients
Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features in Patients With Pre-malignant Pancreatic Cystic Neoplasms Using Magnetic Resonance Imaging and Endoscopic Ultrasound
This study is trying to see if measuring fat in the pancreas and liver can help find early signs of dangerous pancreatic cysts in patients who might be at risk for pancreatic cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 236 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Shatin, New Territories) |
| Trial ID | NCT05334836 on ClinicalTrials.gov |
What this trial studies
This study aims to determine the prevalence of pancreatic steatosis and its correlation with high-risk features of pancreatic cysts. It involves screening patients with pancreatic cystic lesions presumed to be intraductal papillary mucinous neoplasms (IPMN) or mucinous cystic neoplasms (MCN) using MRI for quantifying pancreatic and liver fat. The goal is to enhance early detection and surveillance of pre-malignant lesions to improve outcomes for patients at risk of pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 or older with at least one pancreatic cystic lesion or healthy subjects.
Not a fit: Patients with known pancreatic cancer, prior pancreatic resection, or significant alcohol consumption may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Other studies have shown promise in using imaging techniques for early detection of pancreatic lesions, indicating that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or older 2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects. 3. Patients who are able to provide written informed consent to participate in the study and comply with the study procedures. Exclusion Criteria: 1. Unable to provide written informed consent 2. Patients with metallic implants or other contraindications to MRI 3. Patients with contraindications for endoscopy due to comorbidities 4. Patients with known pancreatic cancer or prior pancreatic resection 5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Where this trial is running
Shatin, New Territories
- Prince of Wales Hospital, The Chinese University of Hong Kong — Shatin, New Territories, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Raymond S Tang, MD — Chinese University of Hong Kong
- Study coordinator: Felix Sia
- Email: felixsia@cuhk.edu.hk
- Phone: 26370428
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.